, and abnormalities of chromosome 14, which are all associated with a poor prognosis.' The molecular changes responsible for the development and progression of CLL have not been elucidated fully, but both karyotypic and molecular studies have been hampered by the inclusion of patients with prolymphocytic leukaemia (PLL), splenic lymphoma with villus lymphocytes (SLVL), hairy cell leukaemia, and non-Hodgkin's lymphoma (follicular and mantle cell) in leukaemic phase. Unfortunately, no single test is diagnostic of CLL and a combination of morphology and immunophenotyping is required. The situation is confused further by the recent observation that subtypes of CLL exist with atypical features (and often atypical behaviour!).
The aim of this review is therefore to try to clarify what is known about the karyotypic and molecular abnormalities in both typical and atypical CLL and to suggest future studies which may shed further light on this complex disease.
Karyotypic abnormalities in CLL Successful karyotyping of CLL cells was first described in the late 1970s and since then data from many single and multicentre studies have been published. 79 Karyotypic abnormalities may be single (29-32%), double (11-12%), triple or more (12-15%) , with chromosomes 6, 11, 12, 13, and 14 being the most commonly affected.2 '0 " CHROMOSOME 6 Abnormalities of chromosome 6 occur in up to 8% of patients with CLL, with additional abnormalities in about half-for example, trisomy 12, t(l1; 14) .' 10 CHROMOSOME 11 Initial studies showed that abnormalities of chromosome 1 1 occurred in up to 10% of patients with CLL.2 10 11 The commonest abnormality is t(1 1;14)(q13;q32), which is found characteristically in mantle cell lymphoma and PLL. 20 21 It has recently been shown to be associated with atypical CLL in which cells are CD23 negative, surface immunoglobulin strongly staining and karyotypic evolution not uncommon. 22 23 Indeed, these studies confirmed earlier reports of a worse prognosis in patients with this abnormality.2 ' As in mantle cell lymphoma, the t(11;14)(qI3;q32) translocation results in rearrangements of the bcl-1 locus on 11 qi 3 with the immunoglobulin heavy chain gene on 14q32.24-28 However, these early studies include many patients with features more in keeping with non-Hodgkin's lymphoma rather than CLL (for example, CD5 or CD23 negative, FMC7 positive) which has led some authors to conclude that bcl-l rearrangements do not occur in CLL, although this is disputed.'2 22 29 It is not unusual for t(1 1;14) to be part of a more complex karyotype.' 10 30 31 Deletions of 11 q were identified in some of the earliest studies of CLL but were thought to be relatively rare.5 6 10 11 30 31 Several recent studies, however, have shown that del (11 q) is one of the commonest abnormalities in patients with typical CLL (14-27%) and may be associated with advanced progressive disease and karyotypic evolution. [32] [33] [34] Studies using fluorescence in situ hybridisation (FISH) and YAC (yeast artificial chromosome) probes have revealed a genomic region of [7] [8] [9] Mbp that is located proximal to the MLL gene on 1 1q23.35 These studies indicate the likely presence of a previously unrecogn-ised tumour suppressor gene in the region of 11 q23 which is important in the pathogenesis of CLL. Interestingly, a recent study revealed a novel fusion between the promyelocytic leukaemic zinc finger gene (on 11 q23) and the retinoic acid receptor (x gene (on 1 7q2 1) in five of 11 patients with CLL.36 CHROMOSOME 12 Early studies showed that trisomy 12 is one of the commonest chromosomal abnormalities in CLL, occurring in about 20% of all patients and associated with a poor prognosis.2 8 101' It arises from duplication of one chromosome 12 with retention of the other copy rather than the loss of one chromosome 12 and triplication of the other.37 38 The use of FISH permits detection of trisomy 12 12 virtually never occurs in association with deletions of 13q14, which is one of the commonest abnormalities in typical CLL (see later); however, molecular studies using the retinoblastoma gene (Rb-i; situated at 13q14) have shown that 6% of patients with CLL have both trisomy 12 and deleted Rb-1 genes. 52 Other structural abnormalities-for example, translocations/deletions of chromosome 12, have been described involving, amongst others, p 1 1, p 12, p 13, q13, and q24, but these occur in less that 3% of patients.2 10 II Several oncogenes reside on chromosome 12 but none seem to be important in the pathogenesis of CLL. 53 The murine doubleminute-2 gene (MDM-2) is located at 12q13-14 and encodes in 90 kDa protein, which complexes with both wild type and mutated p53 and inhibits its growth regulating properties.54 MDM-2 can overcome the growth suppressing activity of p53 with a similar functional consequence to that of p53 mutation. 55 In view of the possible role of p53 mutations in the pathogenesis of CLL (see later) several studies looking at MDM-2 concentrations have been reported. Overexpression of MDM-2 mRNA occurs in up to 73% of patients with CLL, but no amplification of the MDM-2 gene has been demonstrated.56 57 Interestingly, MDM-2 overexpression is found more frequently in patients with advanced clinical disease, but 82% (14/17) of patients expressed wild type p53.58 Thus, it seems that overexpression of MDM-2 may play a role in the pathogenesis or progression of CLL. Unlike p53 mutations in CLL, however, MDM-2 overexpression does not seem to confer drug resistance. 59 To date there have been no studies reported specifically looking at MDM-2 expression in cells from patients with CLL and trisomy 12. Caution should perhaps also be exercised in interpreting MDM-2 overexpression, as most studies have compared expression of CLL cells with peripheral blood, lymph node or splenic B lymphocytes rather than the normal counterpart (that is, CD19+/CD5+) of the B-CLL lymphocytes. CHROMOSOME 
13
Abnormalities of chromosome 13, although previously described in B-CLL, were brought to prominence by Fitchett in 1987, who described 14 patients with deletions (9) (more common).2 11 29 Interest in chromosome 17 arose from the identification of the p53 tumour suppresser gene on 17p13, which plays an important role in cell growth, differentiation and ultimately apoptosis.8F86 It was shown to act as a tumour suppresser gene by preventing the onset of tumorigenesis and is inherited as an autosomal recessive trait.87-89 Inactivation of p53 can occur through gene deletions, mutation or single base insertion.
Molecular abnormalities of p53 occur in up to 15% of patients with CLL, are very heterogeneous and usually associated with advanced disease (table 1). 12 9"96 Mutations of p53 are often associated with karyotypic abnormalities of chromosome 17 (usually monosomy 17 or del (1 7p) and loss of heterozygosity of the normal allele).' 85 92 93 Four studies have shown recently that p53 mutations are associated with drug resistance, which is independent of MDR1/MDR3 status, and results in a significantly worse prognosis.92 .. .. .. Indeed, in multivariate analysis it is one of the most important prognostic factors. Patients are resistant to a wide range of single chemotherapy agents-for example, chlorambucil, prednisolone, fludarabine, and deoxycoformycin, as well as the multidrug regime, CHOP (cyclophosphamide, adriamycin, vincristine, prednisolone). As the mode of action of many chemotherapy agents is to induce apoptosis, it is thought that p53 mutations prevent initiation of the apoptotic pathway.98
The exact role of p53 mutations in the pathogenesis of CLL is unclear as it has not been studied extensively. It is known that p53 mutations are more frequent in Richter syndrome, but analysis of paired samples (that is, CLL and Richter sample) have not given consistent results.9' Matolcsy et al96 studied six patients but found p53 mutations in only two. One patient had a p53 mutation in the Richter clone but the immunoglobulin rearrangement was different to the preceding CLL clone, indicating the emergence of a totally unrelated clone. In the other patient an identical p53 mutation was present in the CLL and Richter clones, suggesting that the p53 mutation was not responsible for the histological transformation. A recent patient with atypical CLL (t(1 1;14) ) reported by Cuneo et al99 developed a p53 mutation (A to G at codon 234) during Richter transformation which was not present during the CLL phase; this suggested a pathogenic role for this p53 mutation. The identical p53 mutation, however, has been described in a patient with stage I typical CLL, a long doubling time and loss of 17p 13 heterozygosity (that is, early non-progressive disease), indicating that this particular mutation alone is insufficient to lead to disease progression or transformation. 12 CHROMOSOME 
18
Abnormalities of chromosome 18 are rare (about 3% of patients) in CLL.2 "' Monosomy, trisomy and translocations have been described. The commonest translocations usually involve 18q21, the bcl-2 gene, with 2pll (K light chain locus), 14q32 (IgH locus) and 22ql 1 (k light chain locus). In all of these patients bcl-2 is juxtaposed to the above genes with rearrangement of bcl-2.27 83 100-105
Various break-points have been described within the minor and major break-point regions and the variant cluster regions.27 83104 Bcl-2 rearrangements are not found in CLL cells lacking karyotypic abnormalities of 18q21. To date, no oncogenes have been identified which are critical to the development and progression of CLL. Bcl-l and bcl-2 rearrangements are extremely rare or probably do not occur at all in true CLL. The mechanism of bcl-2 protein overexpression and its clinical importance certainly warrants further investigation. The recent observation that several cytokines-for example, interleukin-4, a or y interferon, can increase bcl-2 concentrations and inhibit apoptosis is interesting and perhaps suggests that autocrine production of cytokines may be pathogenically important.' Similarly, the development and importance of p53 mutations, especially in exons other than 5-8, further studies looking at p53 status and MDM-2 expression.
In conclusion, although we are much closer to identifying genes relevant to CLL there is still a lot to be done. When dealing with relatively "benign" disorders, the urgency for the absolutely correct diagnosis is not so great but if we wish to increase our understanding, the distinction between typical, atypical and mixed CLL must be more fully appreciated and specific karyotypic and molecular studies devised for these different disorders. We are moving closer to a new classification of CLL based upon morphological, immunophenotypic, karyotypic, and perhaps genetic abnormalities, but CLL epitomises the well known fact that it is more difficult to study a common, heterogeneous disorder with a relatively good prognosis than a rare lethal disease such as acute myeloid leukaemia. 
